DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
compose your message
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Effort set to help sickle cell patients manage meds
Vanderbilt University Medical Center is part of a 6-year, $4.4 million grant from the National Institutes of Health to improve the use of prescribed medication by sickle cell patients.
Funded by the National Heart, Lung and Blood Institute (Grant No. 1U01HL133996-01), the new Sickle Cell Disease Implementation Program includes researchers from St. Jude Children’s Research Hospital, the University of Memphis, Methodist University Hospital, Baptist Memorial Hospital and Vanderbilt.
The team will jointly develop, assess and integrate mobile health applications to manage hydroxyurea treatments among patients with sickle cell disease and identify barriers to medical care and any constraints on proper use of the medication.
In addition, the team will also make the findings of the study available nationwide to encourage best practice and wider use of hydroxyurea in the national sickle cell community.
education & researchAssociation of Antibiotic Choice With Hospital Length of Stay and Risk Factors for Readmission in Patients With Sick...Study objective: We determine the assoc...
education & researchManagement of male fertility in sickle cell disease before and after hydroxycarbamideHydroxycarbamide (hydroxyurea or HU) is ...
news & eventsQ&A With Regina Hartfield, New CEO of the SCDAARegina Hartfield is set to become the pr...
people & placesWHATZ DA COUNTWDC on SCT has dedicated his Organizatio...
people & placesSickle Cell Anemia Association of QuebecThe Sickle Cell Association of Quebec is...
videos & visualsMeet the oneSCDvoice community!https://www.onescdvoice.com/wp-content/u...
news & eventsImara Reports Favorable Preclinical and Phase 1 Data on IMR-687 in Sickle Cell DiseaseImara Inc. today announced it will repor...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.